Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evorpacept with Venetoclax and Azacitidine in AML
NCT04755244Phase 1Terminated
- Sponsor
- ALX Oncology
- Start
- May 2021
- Primary completion
- May 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of evorpacept in acute myeloid leukemia (AML), sponsored by ALX Oncology. Primary endpoints: Dose Limiting Toxicities at 28 days and Composite complete remission rate at 6 months. Started May 2021; status: terminated.
02
Drugs
evorpacept
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04755244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04755244.